A Phase 2 interventional study of BRM424 Ophthalmic Solution - Dose1 and BRM424 Ophthalmic Solution - Dose2 in Neurotrophic Keratitis, sponsored by BRIM Biotechnology Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-28.
Sponsored by BRIM Biotechnology Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Keratitis with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Keratitis · United States.
Among the 34 studies in Keratitis with a site in United States, this one is the 22nd largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2024, is one of 9 in phase 2, and was the 31st registered.
108 studies on the registry are indexed under Keratitis; 19 are open to participants now.
Browse Keratitis studies →4 of the 34 studies in Keratitis with a site in United States are open now. Recruiting first, the newest first:
TearSolutions, Inc. · Sites in United States
Ages 18+
Krystal Biotech, Inc. · Sites in United States
Ages 18+
Stanford University · Sites in United States, Brazil, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Keratitis studies recruiting now, 6 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 5 · Phase 4 3
First in 1997; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 40 across 70 interventional studies indexed under Keratitis.
Median enrollment 60 across the 25 interventional studies, 60 across the 9 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 34 have an industry lead sponsor. The 10 most frequent:
BRIM Biotechnology Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
BRIM Biotechnology Inc. has 1 study filed under Keratitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Keratitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06999733Krystal Biotech, Inc.A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis | 2026-12 |
| NCT07568730TearSolutions, Inc.A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies in Keratitis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BRM424 Ophthalmic Solution - Dose1
Drug: BRM424 Ophthalmic Solution - Dose2
A topical drop of BRM424 ophthalmic solution.
A topical drop of BRM424 ophthalmic solution.
Proportion of patients achieving complete healing of the PED or corneal ulcer determined by corneal fluorescein staining
Time frame: at or before 4 weeks
Started Jul 2024 (actual). Primary completion is estimated for Aug 2025, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulipiftide
BRIM Biotechnology Inc.